Sinopharm Officially Becomes the 6th Booster Vaccine in Indonesia, Here Are the Side Effects
The Covid-19 booster vaccine used in Indonesia is increasing. The Food and Drug Supervisory Agency (BPOM) has issued an emergency use of authorization (EUA) permit as a follow-up or booster dose for the Sinopharm vaccine.
In a written statement quoted from the setkab.go..id page, Head of BPOM Penny K. Lukito said, according to the requirements for emergency use, BPOM has evaluated the efficacy and safety aspects referring to the Covid-19 vaccine evaluation standard for the Sinopharm vaccine as a booster dose. homologs for adults 18 years and over. "This decision makes the Sinopharm Vaccine the 6th vaccine used as a booster dose in the country," he explained. The five COVID-19 vaccines that previously received emergency use permits to be used as booster vaccines are the CoronaVac vaccine produced by PT Bio Farma, the Pfizer vaccine, the AstraZeneca vaccine, the Moderna vaccine, and the Zifivax vaccine. This Sinopharm vaccine has been registered by PT Kimia Farma for the use of a homologous booster in adults 18 years of age or older who have received a complete primary dose for at least six months.
|•SOURCE•| Articles :KONTAN | Image :IMC HEALTHCARE |
READ MORE
|• NATIONAL •|Bank Sinarmas Cares for literacy
|• INTERNATIONAL •|Crocodile Conservation in muba
|• TECHNOLOGY •|Smartfren Opens Up About News
|• SOCIAL •|Eka Tjipta Foundation and Kanisius Hold Vaccination
|• BUSINESS •|CPO Price Heats up
0 comments: